Dose-ranging study of riluzole in amyotrophic lateral sclerosis
暂无分享,去创建一个
P. Leigh | V. Meininger | L. Lacomblez | G. Bensimon | P. Guillet | V Meininger | P Guillet | L Lacomblez | G Bensimon | P. N Leigh | Amyotrophic Lateral SclerosisRiluzole Study Group
[1] I. Hemmi,et al. Clinical Statistics in 515 Fatal Cases of Motor Neuron Disease , 1984 .
[2] M. Debono,et al. Inhibition by riluzole of electrophysiological responses mediated by rat kainate and NMDA receptors expressed in Xenopus oocytes. , 1993, European journal of pharmacology.
[3] V. Meininger,et al. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. , 1994, The New England journal of medicine.
[4] P. Shaw,et al. Excitotoxicity and motor neurone disease: A review of the evidence , 1994, Journal of the Neurological Sciences.
[5] Raymond J. Carroll,et al. Estimation and comparison of changes in the presence of informative right censoring by modeling the censoring process , 1988 .
[6] J. Glowinski,et al. Antagonism by riluzole of entry of calcium evoked by NMDA and veratridine in rat cultured granule cells: evidence for a dual mechanism of action , 1994, British journal of pharmacology.
[7] B. Brooks,et al. El escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis , 1994, Journal of the Neurological Sciences.
[8] P. Cardy. Research, care and the associations: An era for partnership , 1994, Journal of the Neurological Sciences.
[9] B. Meldrum. Amino acids as dietary excitotoxins: A contribution to understanding neurodegenerative disorders , 1993, Brain Research Reviews.
[10] F. Norris,et al. Onset, natural history and outcome in idiopathic adult motor neuron disease , 1993, Journal of the Neurological Sciences.
[11] J. Rothstein. Excitotoxic mechanisms in the pathogenesis of amyotrophic lateral sclerosis. , 1995, Advances in neurology.
[12] P. Sindou,et al. Neuroprotective effects of riluzole in ALS CSF toxicity. , 1994, Neuroreport.
[13] R J Dunn,et al. Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. , 1994, Molecular pharmacology.
[14] M. Gurney,et al. Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis , 1996, Annals of neurology.
[15] S. Vollset,et al. Prognostic factors and survival in amyotrophic lateral sclerosis. , 1994, Neuroepidemiology.
[16] Kurtzke Jf. Risk factors in amyotrophic lateral sclerosis. , 1991 .
[17] A. Eisen,et al. Duration of amyotrophic lateral sclerosis is age dependent , 1993, Muscle & nerve.
[18] J. Whitehead,et al. A FORTRAN program for the design and analysis of sequential clinical trials. , 1983, Computers and biomedical research, an international journal.
[19] R. Tarone,et al. Tests for trend in life table analysis , 1975 .
[20] A. Doble,et al. Pertussis toxin pretreatment abolishes the inhibitory effect of riluzole and carbachol on d[3H]aspartate release from cultured cerebellar granule cells , 1992, Neuroscience Letters.
[21] J. Nadler,et al. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. , 1993, European journal of pharmacology.
[22] J. Kurtzke. Risk factors in amyotrophic lateral sclerosis. , 1991, Advances in neurology.
[23] M. Lazdunski,et al. Expression cloning of an epithelial amiloride‐sensitive Na+ channel , 1993, FEBS letters.